PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 440-447

  Tang, A H ^a   Franklin, S R ^a   Himes, C S ^a   Smith, M W ^a   Tenbrink, R E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 FLUOROPHENYL) 4 [2 (ISOCHROMAN 1 YL)ETHYL]PIPERAZINE; APOMORPHINE; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; METHYLPHENIDATE; MUSCARINIC RECEPTOR; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CLIMBING; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; STEREOTYPY;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CLOZAPINE; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN;

EID: 0030987261     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. ANISMAN, H., HAHN, B., HUFFMAN, D. AND ZACHARKO, R. M.: Stressor invoked exacerbation of amphetamine-elicited perseveration. Pharmacol. Biochem. Behav. 23: 173-183, 1985.
2. BALDESSARINI, R. J., HUSTON-LYONS, D., CAMPBELL, A., MARSH, E. AND COHEN, B. M.: Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br. J. Psychiat. 160: 12-16, 1992.
3. BROWNE, R. G. AND KOE, B. K.: Clozapine and agents with similar behavioral and biochemical properties. In Drug Discrimination: Application in CNS Pharmacology, ed. by F. C. Colpaert and J. L. Slangen, pp. 241-254, Elsevier Biomedical Press, Amsterdam, 1982.
4. BYMASTER, F. P., CALLIGARO, D. O., FALCONE, J. F., MARSH, R. D., MOORE, N. A., TYE, N. C., SEEMAN, P. AND WONG, D. T.: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96, 1996.
5. CHENG, Y. C. AND PRUSOFF, W. H.: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3103, 1973.
6. 2 dopamine receptor in rat and bovine caudate nucleus. Nature 343: 266-269, 1990.
7. 2 dopamine receptors. Mol. Pharmacol. 45: 51-60, 1994a.
8. 4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J. Biol. Chem. 269: 11813-11819, 1994b.
9. COSTALL, B., NAYLOR, R. J. AND OLLEY, J. E.: Stereotypic and anticataleptic activities of amphetamine after intracerebral injections. Eur. J. Pharmacol. 18: 83-94, 1972.
10. COSTALL, B., FORTUNE, D. H., NAYLOR, R. J. AND NOHRIA, V.: The mesolimbic system, denervation and the climbing response in the mouse. Eur. J. Pharmacol. 66: 207-215, 1980.
11. CREESE, I., BURT, D. R. AND SNYDER, S. H.: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483, 1976.
12. 9-THC, LSD-25 and scopolamine on continuous, spontaneous alternation in the Y-maze. Psychopharmacology 32: 171-182, 1973.
13. 1A receptor. Nature 335: 358-360, 1988.
14. FINNEY, D. J.: Statistical Methods in Biological Assay. Charles Griffin & Co., London, 1952.
15. FRANKLIN, S. R. AND TANG, A. H.: Discriminative stimulus effects of clozapine in rats. Behav. Pharmacol. 5: 113, 1994. (Abstract).
16. GOLDSTEIN, J. M. AND ARVANITIS, L. A.: ICI 204,636 (SEROQUEL): A dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev. 1: 50-73, 1995.
17. HAHN, B., ZACHARKO, R. M. AND ANISMAN, H.: Alterations of amphetamine elicited perseveration and locomotor excitation following acute and repeated stressor application. Pharmac. Biochem. Behav. 25: 29-33, 1986.
18. 2 receptors. J. Pharmacol. Exp. Ther. 263: 276-284, 1992.
19. JANSSEN, P. A. J. AND NIEMEGEERS, C. J. E.: Analysis of the influence of haloperidol and pharmacologically related drugs on learned avoidance-escape habits of the Wistar rat in a "jumping box" situation. Arzneimittel-Forsch. 11: 1037-1043, 1961.
20. 2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc. Natl. Acad. Sci. U.S.A. 87: 928-932, 1990.
21. KANE, J., HONIGFELD, G., SINGER, J. AND MELTZER, H. Y.: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45: 789-796, 1988.
22. KOKKINDIS, L. AND ANISMAN, H.: Perseveration and rotational behavior elicited by d-amphetamine in a Y-maze exploratory task: Differential effects of intraperitoneal and unilateral intraventricular administration. Psychopharmacology 52: 123-128, 1977.
23. KRUPP, P. AND BARNES, P.: Clozapine-associated agranulocytosis: risk and aetiology. Br. J. Psychiatry 160:(Suppl. 17): 38-41, 1992.
24. 4 receptor. J. Med. Chem. 39: 1941-1942, 1996.
25. KURIBARA, H. AND TADOKORO, S.: Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. Pharmac. Biochem. Behav. 14: 181-192, 1981.
26. 2 receptors. Psychopharmacology 112: S40-S54, 1993.
27. LIEBERMAN, J. A.: Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br. J. Psychiatry 163(Suppl. 22): 7-18, 1993.
28. MELTZER, H. Y.: Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99: S18-S27, 1989.
29. MOORE, N. A. AND AXTON, M. S.: Production of climbing behavior in mice requires both D1 and D2 receptor activation. Psychopharmacology 94: 263-266, 1988.
30. MOORE, N. A., TYE, N. C., AXTON, M. S. AND RISIUS, F. C.: The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J. Pharmacol. Exp. Ther. 262: 545-551, 1992.
31. NIELSEN, E. B.: Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 94: 115-118, 1988.
32. ORTMANN, R., BISCHOFF, S., RADEKE, E., BUECH, O. AND DELINI-STULA, A.: Correlations between different measures of serotonin activity of drugs. Study with neuroleptics and serotonin receptor blockers. Naunyn-Schmeideberg Arch. Pharmac. 321: 265-270, 1982.
33. PEROLTKA, S. J., LEBOVITZ, R. M. AND SNYDER, S. H.: Two distinct serotonin receptors with different physiological functions. Science 212: 827-829, 1981.
34. PROTAIS, P., COSTENTIN, J. AND SCHWARTZ, J. C.: Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors striatum. Psychopharmacology 50: 1-6, 1976.
35. ROBERTSON, A. AND MACDONALD, C.: Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy. Pharmac. Biochem. Behav. 21: 97-101, 1984.
36. SCHOTTE, A., JANSSEN, P. F. M., MEGENS, A. A. H. P. AND LEYSEN, J. E.: Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631: 191-202, 1993.
37. SMELIK, P. G. AND ERNST, A. M.: Role of nigro-neostriatal dopaminergic fibers in compulsive gnawing behavior in rats. Life Sci. 5: 1485-1488, 1966.
38. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614, 1991.
39. YADIN, E., FRIEDMAN, E. AND BRIDGER, W. H.: Spontaneous alternation behavior: An animal model for obsessive-compulsive disorder? Pharmacol. Biochem. Behav. 40: 311-315, 1991.